Advisory Board &
Further Collaboration Boards
Hypertension, a leading cause of heart and kidney diseases, affects over 80 million people in the EU and contributes to one million deaths annually. Despite the availability of treatments, many patients continue to face significant health risks due to inadequate blood pressure control.
SGLT2 inhibitors, a class of drugs commonly used for diabetes and heart failure, have shown potential in lowering blood pressure and providing organ protection due to pleiotropic effects. However, further research is required to confirm their effectiveness in hypertension management
Project Advisory Board
Some board name
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
Name Goes Here
Munich, Germany
Name Goes Here
Munich, Germany
Name Goes Here
Munich, Germany
Name Goes Here
Munich, Germany
Name Goes Here
Munich, Germany
Name Goes Here
Munich, Germany
Find out more here
New EU-funded Project Aims to Transform Hypertension Treatment
SGLT2 HYPE is a guideline-relevant clinical trial aiming to establish SGLT2 inhibitors as a new standard in high blood pressure therapy, ultimately addressing one of the leading causes of premature mortality in Europe